Novartis | NVS - Selling And Administration Expenses



Novartis reported $3.44B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
AbbVie USD 3.25B 40M Jun/2025
Amgen USD 1.69B 4M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Bausch Health Companies USD 894M 27M Jun/2025
Biogen USD 583.8M 11.3M Jun/2025
Bristol-Myers Squibb USD 1.71B 129M Jun/2025
Canopy Growth CAD 40.12M 504K Jun/2025
Corcept Therapeutics USD 103.85M 13.19M Jun/2025
Drreddys Laboratories INR 23.18B 1.59B Jun/2025
Eli Lilly USD 2.75B 390.8M Jun/2025
Gilead Sciences USD 1.36B 100M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
Glaxosmithkline GBP 2.09B 609M Jun/2025
J&J USD 5.89B 777M Jun/2025
Merck USD 2.63B 104M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Novartis USD 3.44B 60M Jun/2025
Pacira USD 77.19M 9.58M Jun/2025
Perrigo USD 273.1M 8.1M Jun/2025
Pfizer USD 3.42B 406M Jun/2025
Prestige Brands USD 28.46M 35.6M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Sanofi EUR 2.63B 408M Jun/2025
Sanofi EUR 2.32B 1.08B Jun/2025
Supernus Pharmaceuticals USD 62.22M 27.72M Jun/2025
Zoetis USD 617M 54M Jun/2025